Industry Briefs: September 10, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: September 10, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Boehringer Ingelheim has implemented a a flexible set-up and operational approach for disposable technologies within its biopharmaceutical development and manufacturing network. Read More

CSL Biotherapies has been awarded a contract by the US Department of Health and Human Services to supply prepandemic and pandemic vaccine antigens and related services to the US national stockpile. Read More

ICON has expanded its US and United Kingdom bioanalytical facilities to supply biomarker and cell-based assay services. Read More

MedImmune and WuXi AppTec have formed a joint venture to develop and commercialize MEDI5117, a novel biologic for autoimmune and inflammatory diseases, in China. Read More

Patheon has sold its global secondary clinical packaging and clinical distribution services business to Bellwyck Packaging Solutions, a priovider of clinical-trial and contract services for secondary packaging. Read More

FDA has approved Pfizer’s Bosulif (bosutinib), new molecular entity for treating chronic myelogenous leukemia. Read More

Sigma-Aldrich and AB SCIEX, a manufacturer of mass spectrometry instruments, have agreed to globally distribute AB SCIEX’s mass spectrometry-based tagging chemistries, called SCIEX iChemistry Solutions, for applications in basic research and applied markets. Read More

People Notes

Aceto has announced that Albert Eilender will step down from his position as CEO, effective Jan. 2, 2013. He will remain as chairman of the board of directors. Salvatore Guccione has been elected to succeed Eilender as CEO, also effective Jan. 2, 2013. Read More

AMRI has appointed Daniel Conlon as senior director of business development. Read More

SciClone Pharmaceuticals has announced announced that Mark Lotter will resign from the position of CEO of the company’s China operations division at the end of 2012. A replacement candidate has not been announced. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here